Cargando…

Objective measurement of therapeutic response in breast cancer using tumour markers.

In 65 patients with systemic breast cancer, a biochemical response index using three tumour markers in combination, carcinoembryonic antigen (CEA), carbohydrate antigen 15-3 (CA 15-3) and erythrocyte sedimentation rate (ESR), allowed objective biochemical assessment of response to endocrine therapy....

Descripción completa

Detalles Bibliográficos
Autores principales:	Robertson, J. F., Pearson, D., Price, M. R., Selby, C., Blamey, R. W., Howell, A.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1991
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977677/ https://www.ncbi.nlm.nih.gov/pubmed/1911226

Ejemplares similares

An objective biochemical assessment of therapeutic response in metastatic breast cancer: a study with external review of clinical data.
por: Williams, M. R., et al.
Publicado: (1990)

Continuous chemotherapy in responsive metastatic breast cancer: a role for tumour markers?
por: Dixon, A. R., et al.
Publicado: (1993)

Epithelial mucin core antigen (EMCA) in assessing therapeutic response in advanced breast cancer--a comparison with CA15.3.
por: Dixon, A. R., et al.
Publicado: (1993)

Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer.
por: Howell, A., et al.
Publicado: (1996)

Tumour markers in breast cancer.
por: Cove, D. H., et al.
Publicado: (1979)

Prognostic factors at the time of diagnosis of metastatic breast cancer.
por: Robertson, J. F., et al.
Publicado: (1998)

Comparison of two oestrogen receptor assays in the prediction of the clinical course of patients with advanced breast cancer.
por: Robertson, J. F., et al.
Publicado: (1992)

Serum proteins as tumour markers for breast cancer.
por: Mattison, P., et al.
Publicado: (1981)

Goserelin (Zoladex) in premenopausal advanced breast cancer: duration of response and survival.
por: Dixon, A. R., et al.
Publicado: (1990)

Response in post-menopausal patients on ICI 118630.
por: Robertson, J. F., et al.
Publicado: (1987)

Tumour epithelial cellularity and quantitative oestrogen receptor values in primary breast cancer.
por: Mumford, C. J., et al.
Publicado: (1983)

Tumour aneuploidy, prognostic parameters and survival in primary breast cancer.
por: Owainati, A. A., et al.
Publicado: (1987)

The measurement and therapeutic implications of circulating tumour cells in breast cancer
por: Smerage, J B, et al.
Publicado: (2006)

Potential for cost economies in guiding therapy in patients with metastatic breast cancer.
por: Robertson, J. F., et al.
Publicado: (1995)

Frequency of screening for breast cancer
por: Blamey, R.W.
Publicado: (1989)

Early-onset breast cancer--histopathological and prognostic considerations.
por: Kollias, J., et al.
Publicado: (1997)

Thymidine kinase in breast cancer.
por: Robertson, J. F., et al.
Publicado: (1990)

Relationship between oestrogen-receptor content and histological grade in human primary breast tumours.
por: Maynard, P. V., et al.
Publicado: (1978)

Spleen Weight in Rats During Tumour Growth and in Homograft Rejection
por: Blamey, R. W., et al.
Publicado: (1971)

Methods in Cancer Research, Vol XIX Tumour Markers
por: Price, M. R.
Publicado: (1982)

Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival.
por: Pinder, S. E., et al.
Publicado: (1995)

Oestrogen-regulated genes in breast cancer: association of pLIV1 with response to endocrine therapy.
por: McClelland, R. A., et al.
Publicado: (1998)

Season of initial detection in breast cancer.
por: Galea, M. H., et al.
Publicado: (1991)

The Primary Implantation of Human Tumours to the Hamster Cheek Pouch
por: Williams, Dorothy E., et al.
Publicado: (1971)

Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy.
por: Archer, S. G., et al.
Publicado: (1995)

Objective assessment of tumour response to therapy based on tumour growth kinetics
por: Mehrara, E, et al.
Publicado: (2011)

Objective assessment of tumour response to therapy based on tumour growth kinetics
por: Mehrara, E, et al.
Publicado: (2011)

The Chemical Induction of Breast Tumours in the Rat: Hormonal Factors in Tumour Production
por: Howell, J. S.
Publicado: (1960)

E-cadherin as a prognostic indicator in primary breast cancer
por: Parker, C, et al.
Publicado: (2001)

Metallothionein expression in human breast cancer.
por: Goulding, H., et al.
Publicado: (1995)

Ki67 immunostaining in primary breast cancer: pathological and clinical associations.
por: Bouzubar, N., et al.
Publicado: (1989)

Breast mammography and tumour volume.
por: Robertson, J. F., et al.
Publicado: (1987)

The use of tumour markers CEA, CA-195 and CA-242 in evaluating the response to chemotherapy in patients with advanced colorectal cancer.
por: Ward, U., et al.
Publicado: (1993)

c-erbB-2 oncoprotein expression in primary and advanced breast cancer.
por: Lovekin, C., et al.
Publicado: (1991)

Mathematical modelling of tumour response in primary breast cancer.
por: Cameron, D. A., et al.
Publicado: (1996)

Bony metastases from breast cancer - a study of foetal antigen 2 as a blood tumour marker
por: Cheung, Kwok-Leung, et al.
Publicado: (2010)

Estrogen receptors and breast cancer.
por: Nicholson, R I, et al.
Publicado: (1981)

Breast cancer expression of YKL-40 correlates with tumour grade, poor differentiation, and other cancer markers
por: Shao, R, et al.
Publicado: (2011)

Oestrogen receptors in primary breast cancer.
por: Williams, M. R., et al.
Publicado: (1985)

International criteria for measurement of tumour response
por: Ollivier, L., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_de5u2vt05m3lepthe59a9ar4br